Searched for
SWISS DRUGMAKER NOVARTIS
Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...- India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
- Novartis experimental actinium-based drug shows promise in prostate cancer treatment: StudyNovartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, e...
- Novartis sharpening India strategy as a pure-play innovatorNovartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...
- Global Markets | European shares subdued as US-Iran talks stall; corporate earnings on tapEuropean shares were muted on Tuesday as investors braced for a week packed with central bank meetings and corporate earnings, while weighi...
- Novartis to buy experimental breast cancer drug in up to $3 billion dealSwiss drugmaker Novartis is set to acquire a promising breast cancer drug candidate from US biotech firm Synnovation Therapeutics. The deal...
- Novartis signs up to $5.2 billion heart drugs licensing deal with China's ArgoNovartis has entered into a licensing and options agreement with Argo Biopharmaceutical, valued at up to $5.2 billion. The deal encompasses...
- Novartis agrees to make ingredients Roche's Actemra for COVID-19 patientsThe arrangement is the third transaction signed by Novartis following agreements with BioNTech and CureVac to make therapies for other firm...
- Novartis to cut 2,200 jobs in Switzerland to boost profitabilityNovartis will cut about 2,200 jobs in Switzerland over the next four years as it consolidates production and shifts positions elsewhere to ...
- Rs 2,000 crore Novartis deal to help Sun Pharma rise in JapanThe discussions between Sun Pharma and Novartis, according to people privy to the matter, pertain to hiving off a handful of older products.
- Novartis buys another 2.5% in Israel's Gamida CellNovartis will not have rights or options to Gamida Cell products or technology under the terms of the agreement.
- Cipla asks government to revoke five patents held by NovartisCipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...
- Novartis India vice-chairman & managing director, Ranjit Shahani says company now focuses on new products, business growthNovartis India has over the past year launched three successful patented drugs and over 12 generic drugs that have helped it expand its pre...
- Novartis, Panacea call off their vaccine joint ventureSwiss drugmaker Novartis' subsidiary Chiron has snapped the eight-year-old joint venture formed with Delhi-based Panacea Biotec.
- Sun Pharma takes Novartis to US Court, seeks permission to market Glivec in USUntil and unless Sun obtains a court decision of non-infringement and/or invalidity on the ’051 patent, it faces the risk of patent infring...
- Novartis wants Indian patent system to improve, compares with ChinaWe will continue with our investments in India, though cautiously. We hope that the ecosystem for intellectual property improves, Ranjit Sh...
- Novartis’ outgoing chief to forgo $78-million exit paySwiss shareholder rights groups had said the agreement should be scrapped after the size of the payoff was reported by a Swiss blog.
- Jupiter Biosciences in talks to buy Swiss pharma co for $10 mHyderabad-based Jupiter Biosciences is in talks to buy privately held Swiss pharma company SynphaBase AG for about $10 million as it looks ...
- Novartis gets US approval for meningitis vaccineNovartis AG said that its meningitis vaccine Menveo has been approved for use in teenagers and adults by the US Food and Drug Administratio...
- Swiss drugmaker Novartis to cut 2,500 jobsSwiss drugmaker Novartis said plans to cut 2,500 jobs in a restructuring programme aimed at generating yearly cost savings of 1.6 billion d...
Load More
